PMID- 35636066
OWN - NLM
STAT- MEDLINE
DCOM- 20220615
LR  - 20220726
IS  - 1090-2163 (Electronic)
IS  - 0008-8749 (Linking)
VI  - 377
DP  - 2022 Jul
TI  - Identification of shared neoantigens in esophageal carcinoma by the combination 
      of comprehensive analysis of genomic data and in silico neoantigen prediction.
PG  - 104537
LID - S0008-8749(22)00061-2 [pii]
LID - 10.1016/j.cellimm.2022.104537 [doi]
AB  - Neoantigens are attractive targets for cancer immunotherapy. The identification 
      of neoantigens shared by different patients could promote the broad application 
      of neoantigen-based immunotherapy. This study aimed to investigate shared 
      neoantigens in esophageal carcinoma. By combining a comprehensive analysis of 
      mutation data of 722 patients with esophageal carcinoma (EC) and in silico 
      neoantigen prediction, we obtained 216 recurrent neoantigen candidates predicted 
      to bind to high-frequency class I human leukocyte antigen (HLA) alleles. We 
      further performed immunogenicity validation tests on five high-frequency 
      HLA-A*0201 binding neoantigens derived from TP53 mutations. The results 
      demonstrated that the peptides p53 H193R(193_203), R248Q(245_254), and 
      R273H(264_274) could efficiently prime peptide-specific CD8(+) T cells to secrete 
      IFN-gamma and lyse mutant peptide-pulsed T2 cells. In conclusion, we obtained a group 
      of shared neoantigen candidates in esophageal carcinoma and validated the 
      immunogenicity of three novel TP53 neoantigens. These peptides might be potential 
      targets for immunotherapy.
CI  - Copyright (c) 2022 Elsevier Inc. All rights reserved.
FAU - Yuan, Yuan
AU  - Yuan Y
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing 
      100049, China; BGI-Shenzhen, Shenzhen 518083, China.
FAU - Chen, Chao
AU  - Chen C
AD  - BGI-Shenzhen, Shenzhen 518083, China; China National GeneBank, BGI-Shenzhen, 
      Shenzhen 518120, China.
FAU - Liu, Songming
AU  - Liu S
AD  - College of Life Sciences, University of Chinese Academy of Sciences, Beijing 
      100049, China; BGI-Shenzhen, Shenzhen 518083, China.
FAU - Xiong, Heng
AU  - Xiong H
AD  - BGI-Shenzhen, Shenzhen 518083, China.
FAU - Huang, Ying
AU  - Huang Y
AD  - BGI-Shenzhen, Shenzhen 518083, China.
FAU - Zhang, Xi
AU  - Zhang X
AD  - BGI-Shenzhen, Shenzhen 518083, China; China National GeneBank, BGI-Shenzhen, 
      Shenzhen 518120, China.
FAU - Zhang, Xiuqing
AU  - Zhang X
AD  - BGI-Shenzhen, Shenzhen 518083, China.
FAU - Li, Bo
AU  - Li B
AD  - BGI-Shenzhen, Shenzhen 518083, China. Electronic address: libo@genomics.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220514
PL  - Netherlands
TA  - Cell Immunol
JT  - Cellular immunology
JID - 1246405
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Peptides)
SB  - IM
MH  - Antigens, Neoplasm/genetics
MH  - CD8-Positive T-Lymphocytes
MH  - *Carcinoma/metabolism
MH  - Genomics
MH  - Humans
MH  - Immunotherapy/methods
MH  - Mutation/genetics
MH  - *Neoplasms
MH  - Peptides
OTO - NOTNLM
OT  - Comprehensive analysis
OT  - Esophageal carcinoma
OT  - Immunotherapy
OT  - Recurrent mutation
OT  - Shared neoantigen
EDAT- 2022/06/01 06:00
MHDA- 2022/06/16 06:00
CRDT- 2022/05/31 13:08
PHST- 2021/09/28 00:00 [received]
PHST- 2022/05/04 00:00 [revised]
PHST- 2022/05/04 00:00 [accepted]
PHST- 2022/06/01 06:00 [pubmed]
PHST- 2022/06/16 06:00 [medline]
PHST- 2022/05/31 13:08 [entrez]
AID - S0008-8749(22)00061-2 [pii]
AID - 10.1016/j.cellimm.2022.104537 [doi]
PST - ppublish
SO  - Cell Immunol. 2022 Jul;377:104537. doi: 10.1016/j.cellimm.2022.104537. Epub 2022 
      May 14.